| 16/05/22 | 07:00:06 | 16 May 2022 | | FDA and FIMEA approve BEXMAB study to begin |
| 12/05/22 | 15:50:01 | 12 May 2022 | | Ex Vivo Data Presented at EHA2022 Congress |
| 09/05/22 | 07:00:07 | 9 May 2022 | | Mol Cancer Ther Publishes Bexmarilimab Research |
| 04/05/22 | 11:15:03 | 4 May 2022 | | Grant of options |
| 22/04/22 | 13:01:02 | 22 Apr 2022 | | Board Changes |
| 22/04/22 | 13:00:03 | 22 Apr 2022 | | Results of AGM |
| 21/04/22 | 16:30:01 | 21 Apr 2022 | | Faron Presents Melanoma Data at EADO |
| 08/04/22 | 15:45:08 | 8 Apr 2022 | | Managers’ Transactions |
| 05/04/22 | 07:00:04 | 5 Apr 2022 | | Faron Closes HIBISCUS Trial |
| 25/03/22 | 09:00:06 | 25 Mar 2022 | | Notice of Faron Pharmaceuticals Ltd’s AGM |
| 25/03/22 | 07:15:06 | 25 Mar 2022 | | Faron´s Annual Report 2021 Published |
| 25/03/22 | 07:00:06 | 25 Mar 2022 | | Financial Statement January 1 to December 31 2021 |
| 14/03/22 | 07:00:12 | 14 Mar 2022 | | Faron Publishes Research From INTEREST Trial |
| 09/03/22 | 07:00:12 | 9 Mar 2022 | | Presentation of Biomarker Data at AACR 2022 |
| 07/03/22 | 07:00:11 | 7 Mar 2022 | | Notice of 2021 Full-Year Results and Annual Report |
| 04/03/22 | 07:00:11 | 4 Mar 2022 | | Faron presents at upcoming conferences |
| 28/02/22 | 17:45:01 | 28 Feb 2022 | | Faron Board Issues Warrants to IPF Partners |
| 28/02/22 | 07:00:09 | 28 Feb 2022 | | Faron Obtains Debt Funding from IPF Partners |
| 23/02/22 | 07:00:02 | 23 Feb 2022 | | Faron Updates on Bexmarilimab Development Program |
| 14/02/22 | 07:00:07 | 14 Feb 2022 | | Faron Announces R&D Day |
| 03/02/22 | 10:40:01 | 3 Feb 2022 | | Scientific Reports Publishes INFORAAA Results |
| 31/01/22 | 13:30:02 | 31 Jan 2022 | | Holdings in Company |
| 31/01/22 | 07:00:09 | 31 Jan 2022 | | Juho Jalkanen Appointed Chief Operating Officer |
| 28/01/22 | 07:00:09 | 28 Jan 2022 | | Grant of options |
| 24/01/22 | 07:00:16 | 24 Jan 2022 | | Faron at Proactive One2One Investor Forum |
| 17/01/22 | 07:00:08 | 17 Jan 2022 | | Faron to Present at Redeye Fight Cancer Seminar |
| 05/01/22 | 07:00:08 | 5 Jan 2022 | | Faron to Present at H.C. Wainwright BioConnect |
| 04/01/22 | 07:00:12 | 4 Jan 2022 | | Faron Appoints Marie-Louise Fjällskog as CMO |
| 21/12/21 | 07:00:05 | 21 Dec 2021 | | Faron’s financial calendar for 2022 |
| 09/12/21 | 07:00:05 | 9 Dec 2021 | | Faron Announces Topline MATINS Biomarker Analysis |
| 01/12/21 | 07:00:08 | 1 Dec 2021 | | Change in Faron’s Management Team |
| 16/11/21 | 07:00:12 | 16 Nov 2021 | | Faron to Present at Jefferies Conference 2021 |
| 09/11/21 | 07:00:03 | 9 Nov 2021 | | Faron awarded EUR 3.8 Million in Arbitration Case |
| 03/11/21 | 15:55:01 | 3 Nov 2021 | | Cellular and Molecular Life Sciences Publication |
| 07/10/21 | 07:00:06 | 7 Oct 2021 | | Exercise of options |
| 05/10/21 | 11:30:07 | 5 Oct 2021 | | Holding(s) in Company |
| 01/10/21 | 14:00:01 | 1 Oct 2021 | | Registration of Placing Shares with Trade Register |
| 01/10/21 | 07:00:07 | 1 Oct 2021 | | Results of Placing and Issue Price |
| 30/09/21 | 16:31:33 | 30 Sept 2021 | | Proposed Issue and Placing of Shares |
| 17/09/21 | 07:00:03 | 17 Sept 2021 | | Presentation of Updated MATINS Data at ESMO |
| 09/09/21 | 07:00:08 | 9 Sept 2021 | | Faron Announces Presentation at ESMO Congress |
| 07/09/21 | 07:00:04 | 7 Sept 2021 | | Faron to Present at H.C. Wainwright Conference |
| 26/08/21 | 07:00:01 | 26 Aug 2021 | | Half-Year Financials, January 1 – June 30 2021 |
| 25/08/21 | 07:00:02 | 25 Aug 2021 | | First Patient Dosed in Phase II/III COVID-19 Trial |
